| Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa AJ Kunz Coyne, A El Ghali, D Holger, N Rebold, MJ Rybak Infectious diseases and therapy 11 (2), 661-682, 2022 | 128 | 2022 |
| Optimization of phage-antibiotic combinations against Staphylococcus aureus biofilms R Kebriaei, SM Lehman, RM Shah, KC Stamper, AJ Kunz Coyne, ... Microbiology Spectrum 11 (3), e04918-22, 2023 | 15 | 2023 |
| Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-Resistant Enterococcus faecium with Preserved Phage Susceptibility AJK Coyne, K Stamper, R Kebriaei, DJ Holger, A El Ghali, T Morrisette, ... Antibiotics 11 (9), 1175, 2022 | 15 | 2022 |
| Sulbactam‐durlobactam: A novel β‐lactam‐β‐lactamase inhibitor combination targeting carbapenem‐resistant Acinetobacter baumannii infections A El‐Ghali, AJ Kunz Coyne, K Caniff, C Bleick, MJ Rybak Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 43 (6 …, 2023 | 9 | 2023 |
| Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure N Rebold, AM Lagnf, S Alosaimy, DJ Holger, P Witucki, A Mannino, ... Microbiology Spectrum 11 (1), e02647-22, 2023 | 9 | 2023 |
| Phage-antibiotic cocktail rescues daptomycin and phage susceptibility against daptomycin-nonsusceptible Enterococcus faecium in a simulated endocardial vegetation ex vivo model AJ Kunz Coyne, K Stamper, A El Ghali, R Kebriaei, B Biswas, M Wilson, ... Microbiology Spectrum 11 (4), e00340-23, 2023 | 6 | 2023 |
| Phage cocktails with daptomycin and ampicillin eradicates biofilm-embedded multidrug-resistant Enterococcus faecium with preserved phage susceptibility. Antibiotics (Basel) 11 … AJ Kunz Coyne, K Stamper, R Kebriaei, DJ Holger, A El Ghali, ... | 6 | 2022 |
| High-dose cefepime vs carbapenems for bacteremia caused by Enterobacterales with moderate to high risk of clinically significant AmpC β-lactamase production AJ Kunz Coyne, A El Ghali, K Lucas, P Witucki, N Rebold, DJ Holger, ... Open Forum Infectious Diseases 10 (3), ofad034, 2023 | 4 | 2023 |
| Impact of ceftolozane–tazobactam vs. best alternative therapy on clinical outcomes in patients with multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa … DJ Holger, NS Rebold, S Alosaimy, T Morrisette, A Lagnf, AC Belza, ... Infectious Diseases and Therapy 11 (5), 1965-1980, 2022 | 4 | 2022 |
| Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes A El Ghali, T Morrisette, S Alosaimy, K Lucas, MG Tupayachi-Ortiz, ... Antimicrobial agents and chemotherapy 67 (10), e00824-23, 2023 | 3 | 2023 |
| Phage-antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa in in vitro static and dynamic biofilm models DJ Holger, A El Ghali, N Bhutani, KL Lev, K Stamper, R Kebriaei, ... Antimicrobial Agents and Chemotherapy 67 (11), e00578-23, 2023 | 2 | 2023 |
| Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-Resistant Enterococcus faecium with Preserved Phage Susceptibility. Antibiotics 2022, 11, 1175 AJ Kunz Coyne, K Stamper, R Kebriaei, DJ Holger, A El Ghali, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2022 | 2 | 2022 |
| Ciprofloxacin in combination with bacteriophage cocktails against multi-drug resistant Pseudomonas aeruginosa in ex vivo simulated endocardial vegetation models A El Ghali, K Stamper, AJ Kunz Coyne, D Holger, R Kebriaei, J Alexander, ... Antimicrobial Agents and Chemotherapy 67 (11), e00728-23, 2023 | 1 | 2023 |
| Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections A El Ghali, AJ Kunz Coyne, K Lucas, M Tieman, X Xhemali, S Lau, ... Microbiology Spectrum 12 (2), e03108-23, 2024 | | 2024 |
| 2118. Comparative Analysis of Cefiderocol Mono-and Combination Therapy for Multi-Drug Resistant Gram-negative Infections AE Ghali, A Kunz-coyne, K Lucas, M Tieman, A Purdy, G Iturralde, ... Open Forum Infectious Diseases 10 (Supplement_2), ofad500. 1741, 2023 | | 2023 |
| High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production AJK Coyne, A El Ghali, K Lucas, P Witucki, N Rebold, DJ Holger, ... | | 2023 |
| 633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints AJ Kunz Coyne, S Allosaimy, KC Molina, L Kang-Birken, AM Lagnf, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 685, 2022 | | 2022 |
| 1422. A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections AE Ghali, AE Ghali, S Allosaimy, T Morrisette, KC Molina, JJ Frens, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 1251, 2022 | | 2022 |
| 679. Traditional vs. Alternative Agents in Patients with Lower Respiratory Tract Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa Susceptible … DJ Holger, AM Lagnf, AC Belza, S Alosaimy, NS Rebold, T Morrisette, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 731, 2022 | | 2022 |
| 1691. Bacteriophage and Protein Synthesis Pathway Inhibitor Combinations: Antibiotic mechanism of action drives antagonistic interactions AJ Kunz Coyne, N Bhutani, D Holger, R Kebriaei, K Stamper, AE Ghali, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 1321, 2022 | | 2022 |
